Alopecia Areata | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2023

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary goal of treatment is to stimulate hair growth through the alleviation of inflammation at sites of hair loss. Topical corticosteroids and topical contact allergens are commonly prescribed; however, tolerability issues, side effects, and the modest efficacy of these treatments underscore the substantial unmet clinical need in AA. The drug development pipeline is active and consists primarily of targeted immunomodulatory agents, with some investigational Janus-activated kinase (JAK) inhibitors (e.g., Pfizer’s ritlecitinib, Concert’s CTP-543) and one recently approved JAK inhibitor (Eli Lilly’s Olumiant [baricitinib]). This report provides an analysis of AA epidemiology, current disease management, unmet needs, and the clinical and commercial potential of emerging therapies.

QUESTIONS ANSWERED

• How large is the diagnosed AA population, and how will its size change between 2021 and 2031? How large are the diagnosed alopecia totalis and universalis populations?
• What are the key unmet clinical needs in AA and to what degree will they be fulfilled by 2031?
• What is the current state of treatment in AA, and how will it evolve over time?
• What emerging AA therapies are viewed by treating dermatologists as most promising, and what sales / uptake will they achieve in AA? How will JAK inhibitors fit into the AA treatment algorithm?

CONTENT HIGHLIGHTS

• Geographies: United States, France, Germany, Italy, Spain, and the United Kingdom.
• Primary research: Six country-specific interviews with thought-leading dermatologists supported by survey data collected for this study.
• Epidemiology: Diagnosed and drug-treated prevalence of AA by country.
• Forecast: Drug-level sales and patient share of key AA therapies in 2031.
• Emerging therapies:
  • Phase II/III: 4 drugs.
  • Phase II: 7 drugs.
  • Coverage of select preclinical and Phase I products.

PRODUCT DESCRIPTION

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.